El Majzoub I, et al. - Researchers sought to focus on the knowledge gap related to the spectrum of immune-related adverse effects among cancer patients visiting Emergency Departments (EDs) via performing a retrospective review of patients treated with immune checkpoint therapy who visited the ED of a comprehensive cancer center between March 1, 2011, and February 29, 2016. Observations suggested that emergency care might be required for cancer patients treated with ipilimumab, nivolumab, or pembrolizumab for having a spectrum of immune-related adverse effects.